• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

启动基础胰岛素类似物与胰高血糖素样肽-1受体激动剂的可滴定固定比例联合治疗：你需要了解的内容。

Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know.

作者信息

Skolnik Neil, Hinnen Debbie, Kiriakov Yan, Magwire Melissa L, White John R

机构信息

Abington Jefferson Health, Abington, PA.

Memorial Hospital Diabetes Center, Colorado Springs, CO.

出版信息

Clin Diabetes. 2018 Apr;36(2):174-182. doi: 10.2337/cd17-0048.

DOI:10.2337/cd17-0048
PMID:29686457
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5898172/
Abstract

Titratable fixed-ratio combinations (FRCs) of a basal insulin and a glucagon-like peptide-1 (GLP-1) receptor agonist are new therapeutic options for people with type 2 diabetes. Two FRCs-insulin degludec/liraglutide and insulin glargine/lixisenatide-have been approved for use in the United States. The two components in these FRCs target different aspects of diabetes pathophysiology, working in a complementary manner to decrease blood glucose while mitigating the side effects associated with each component (hypoglycemia and weight gain with insulin and gastrointestinal side effects with GLP-1 receptor agonists). This article reviews these products and key considerations for their use.

摘要

基础胰岛素与胰高血糖素样肽-1（GLP-1）受体激动剂的可滴定固定比例组合（FRCs）是2型糖尿病患者的新治疗选择。两种FRCs——德谷胰岛素/利拉鲁肽和甘精胰岛素/利司那肽——已在美国获批使用。这些FRCs中的两种成分针对糖尿病病理生理学的不同方面，以互补的方式发挥作用，降低血糖，同时减轻与每种成分相关的副作用（胰岛素导致的低血糖和体重增加以及GLP-1受体激动剂导致的胃肠道副作用）。本文综述了这些产品及其使用的关键注意事项。

相似文献

1
Initiating Titratable Fixed-Ratio Combinations of Basal Insulin Analogs and Glucagon-Like Peptide-1 Receptor Agonists: What You Need to Know.启动基础胰岛素类似物与胰高血糖素样肽-1受体激动剂的可滴定固定比例联合治疗：你需要了解的内容。
Clin Diabetes. 2018 Apr;36(2):174-182. doi: 10.2337/cd17-0048.
2
Rationale for a titratable fixed-ratio co-formulation of a basal insulin analog and a glucagon-like peptide 1 receptor agonist in patients with type 2 diabetes.在 2 型糖尿病患者中，具有基础胰岛素类似物和胰高血糖素样肽 1 受体激动剂的可滴定固定比例复方制剂的理由。
Curr Med Res Opin. 2019 May;35(5):793-804. doi: 10.1080/03007995.2018.1541790. Epub 2018 Nov 27.
3
Fixed-ratio combination therapy for type 2 diabetes: the top ten things you should know about insulin and glucagon-like peptide-1 receptor agonist combinations.2 型糖尿病的固定剂量复方治疗：关于胰岛素和胰高血糖素样肽-1 受体激动剂联合治疗，您应该了解的十大要点。
Postgrad Med. 2018 May;130(4):375-380. doi: 10.1080/00325481.2018.1450058. Epub 2018 Mar 20.
4
Fixed-ratio combination of basal insulin and glucagon-like peptide-1 receptor agonists in the treatment of Japanese people with type 2 diabetes: An innovative solution to a complex therapeutic challenge.基础胰岛素与胰高血糖素样肽-1 受体激动剂固定比例复方制剂治疗日本 2 型糖尿病患者：复杂治疗挑战的创新性解决方案。
Diabetes Obes Metab. 2020 Sep;22 Suppl 4:24-34. doi: 10.1111/dom.14095.
5
Safety and Efficacy of Insulin Degludec/Liraglutide (IDegLira) and Insulin Glargine U100/Lixisenatide (iGlarLixi), Two Novel Co-Formulations of a Basal Insulin and a Glucagon-Like Peptide-1 Receptor Agonist, in Patients With Diabetes Not Adequately Controlled on Oral Antidiabetic Medications.德谷胰岛素/利拉鲁肽（IDegLira）和甘精胰岛素U100/利司那肽（iGlarLixi）两种新型基础胰岛素与胰高血糖素样肽-1受体激动剂复方制剂，用于口服抗糖尿病药物治疗控制不佳的糖尿病患者的安全性和有效性。
Clin Diabetes. 2018 Apr;36(2):149-159. doi: 10.2337/cd17-0064.
6
Fixed-ratio combinations of basal insulin and glucagon-like peptide-1 receptor agonists as a promising strategy for treating diabetes.基础胰岛素与胰高血糖素样肽-1受体激动剂的固定比例组合作为治疗糖尿病的一种有前景的策略。
World J Diabetes. 2023 Mar 15;14(3):188-197. doi: 10.4239/wjd.v14.i3.188.
7
iGlarLixi: A Fixed-Ratio Combination of Insulin Glargine 100 U/mL and Lixisenatide for the Treatment of Type 2 Diabetes.iGlarLixi：一种甘精胰岛素100 U/mL与利司那肽的固定比例组合，用于治疗2型糖尿病。
Ann Pharmacother. 2017 Nov;51(11):990-999. doi: 10.1177/1060028017717281. Epub 2017 Jun 23.
8
Combination of basal insulin and GLP-1 receptor agonist: is this the end of basal insulin alone in the treatment of type 2 diabetes?基础胰岛素与胰高血糖素样肽-1（GLP-1）受体激动剂联合使用：这是否意味着单纯使用基础胰岛素治疗2型糖尿病的终结？
Diabetol Metab Syndr. 2018 Apr 3;10:26. doi: 10.1186/s13098-018-0327-4. eCollection 2018.
9
First fixed-ratio combination of insulin degludec and liraglutide for the treatment of type 2 diabetes.德谷胰岛素与利拉鲁肽的首个固定比例组合用于治疗2型糖尿病。
Drugs Today (Barc). 2015 Mar;51(3):185-96. doi: 10.1358/dot.2015.51.3.2294596.
10
Rationale for, Initiation and Titration of the Basal Insulin/GLP-1RA Fixed-Ratio Combination Products, IDegLira and IGlarLixi, for the Management of Type 2 Diabetes.基础胰岛素/胰高血糖素样肽-1受体激动剂固定比例复方制剂（德谷胰岛素利拉鲁肽和甘精胰岛素利司那肽）用于2型糖尿病管理的理论依据、起始治疗及滴定方法
Diabetes Ther. 2017 Aug;8(4):739-752. doi: 10.1007/s13300-017-0287-y. Epub 2017 Jul 18.

引用本文的文献

1
Treatment persistence and adherence in people with type 2 diabetes switching to iGlarLixi vs free-dose combinations of basal insulin and glucagon-like peptide 1 receptor agonist.2型糖尿病患者从基础胰岛素和胰高血糖素样肽1受体激动剂的自由剂量组合转换为iGlarLixi后的治疗持续性和依从性
J Manag Care Spec Pharm. 2022 Sep;28(9):958-968. doi: 10.18553/jmcp.2022.28.9.958.
2
Practical Guidance on Basal Insulin Initiation and Titration in Asia: A Delphi-Based Consensus.亚洲基础胰岛素起始与滴定的实用指南：基于德尔菲法的共识
Diabetes Ther. 2022 Aug;13(8):1511-1529. doi: 10.1007/s13300-022-01286-0. Epub 2022 Jun 29.
3
Translating iGlarLixi Evidence for the Management of Frequent Clinical Scenarios in Type 2 Diabetes.

本文引用的文献

1
CONSENSUS STATEMENT BY THE AMERICAN ASSOCIATION OF CLINICAL ENDOCRINOLOGISTS AND AMERICAN COLLEGE OF ENDOCRINOLOGY ON THE COMPREHENSIVE TYPE 2 DIABETES MANAGEMENT ALGORITHM - 2017 EXECUTIVE SUMMARY.美国临床内分泌医师协会和美国内分泌学会关于2型糖尿病综合管理算法（2017年执行摘要）的共识声明。
Endocr Pract. 2017 Feb;23(2):207-238. doi: 10.4158/EP161682.CS. Epub 2017 Jan 17.
2
Real-world medication persistence and outcomes associated with basal insulin and glucagon-like peptide 1 receptor agonist free-dose combination therapy in patients with type 2 diabetes in the US.美国2型糖尿病患者中基础胰岛素与胰高血糖素样肽1受体激动剂自由剂量联合治疗的真实世界药物持续性及结局
Clinicoecon Outcomes Res. 2016 Dec 22;9:19-29. doi: 10.2147/CEOR.S117200. eCollection 2017.
3
iGlarLixi 在 2 型糖尿病频繁临床场景管理中的证据转化。
Adv Ther. 2021 Apr;38(4):1715-1731. doi: 10.1007/s12325-020-01614-5. Epub 2021 Feb 23.
4
There Are Great New Medications Out There-Why Aren't We Using Them?有很多很棒的新药——我们为什么不用它们呢？
Clin Diabetes. 2018 Apr;36(2):97-98. doi: 10.2337/cd18-0011.
The Efficacy of IDegLira (Insulin Degludec/Liraglutide Combination) in Adults with Type 2 Diabetes Inadequately Controlled with a GLP-1 Receptor Agonist and Oral Therapy: DUAL III Randomized Clinical Trial.德谷胰岛素利拉鲁肽（胰岛素德谷/利拉鲁肽组合）用于经GLP-1受体激动剂和口服治疗血糖控制不佳的2型糖尿病成人患者的疗效：DUAL III随机临床试验
Diabetes Ther. 2017 Feb;8(1):101-114. doi: 10.1007/s13300-016-0218-3. Epub 2016 Dec 10.
4
Efficacy and Safety of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide in Type 2 Diabetes Inadequately Controlled on Basal Insulin and Metformin: The LixiLan-L Randomized Trial.利西拉来，一种基础胰岛素联合二甲双胍血糖控制不佳的 2 型糖尿病患者的可滴定固定比例复方制剂：LixiLan-L 随机试验的疗效和安全性。
Diabetes Care. 2016 Nov;39(11):1972-1980. doi: 10.2337/dc16-1495. Epub 2016 Sep 20.
5
Safety and efficacy of insulin degludec/liraglutide (IDegLira) added to sulphonylurea alone or to sulphonylurea and metformin in insulin-naïve people with Type 2 diabetes: the DUAL IV trial.在初治2型糖尿病患者中，将德谷胰岛素/利拉鲁肽（IDegLira）添加至单独使用磺脲类药物或磺脲类药物与二甲双胍联合治疗中的安全性和有效性：DUAL IV试验
Diabet Med. 2017 Feb;34(2):189-196. doi: 10.1111/dme.13256. Epub 2016 Oct 7.
6
Benefits of LixiLan, a Titratable Fixed-Ratio Combination of Insulin Glargine Plus Lixisenatide, Versus Insulin Glargine and Lixisenatide Monocomponents in Type 2 Diabetes Inadequately Controlled on Oral Agents: The LixiLan-O Randomized Trial.利西拉来（甘精胰岛素和利西那肽的可滴定固定比例复方制剂）对比甘精胰岛素和利西那肽单药治疗在口服药物控制不佳的 2 型糖尿病患者中的疗效：LixiLan-O 随机试验。
Diabetes Care. 2016 Nov;39(11):2026-2035. doi: 10.2337/dc16-0917. Epub 2016 Aug 15.
7
Prandial Options to Advance Basal Insulin Glargine Therapy: Testing Lixisenatide Plus Basal Insulin Versus Insulin Glulisine Either as Basal-Plus or Basal-Bolus in Type 2 Diabetes: The GetGoal Duo-2 Trial.餐时选择以推进基础胰岛素甘精胰岛素治疗：在 2 型糖尿病中测试利西那肽联合基础胰岛素与赖脯胰岛素，分别作为基础-餐时或基础-追加方案：GetGoal Duo-2 试验。
Diabetes Care. 2016 Aug;39(8):1318-28. doi: 10.2337/dc16-0014. Epub 2016 May 23.
8
Glucose Variability in a 26-Week Randomized Comparison of Mealtime Treatment With Rapid-Acting Insulin Versus GLP-1 Agonist in Participants With Type 2 Diabetes at High Cardiovascular Risk.在伴有高心血管风险的 2 型糖尿病患者中，用速效胰岛素和 GLP-1 激动剂进行餐时治疗 26 周的随机比较中葡萄糖变异性。
Diabetes Care. 2016 Jun;39(6):973-81. doi: 10.2337/dc15-2782. Epub 2016 Apr 19.
9
Effect of Insulin Glargine Up-titration vs Insulin Degludec/Liraglutide on Glycated Hemoglobin Levels in Patients With Uncontrolled Type 2 Diabetes: The DUAL V Randomized Clinical Trial.胰岛素甘精胰岛素滴定上调与胰岛素德谷胰岛素/利拉鲁肽对血糖控制不佳的 2 型糖尿病患者糖化血红蛋白水平的影响：DUAL V 随机临床试验。
JAMA. 2016 Mar 1;315(9):898-907. doi: 10.1001/jama.2016.1252.
10
New combinations in the treatment of COPD: rationale for aclidinium-formoterol.慢性阻塞性肺疾病治疗的新联合用药：阿地氯铵-福莫特罗的理论依据
Ther Clin Risk Manag. 2016 Feb 15;12:209-15. doi: 10.2147/TCRM.S82034. eCollection 2016.